The John Williams Show Weekdays 10 a.m. - noon, 1 - 2 p.m. Focusing on current events, John discusses the news of the day, sports, television programs, movies, and books with a thoughtful perspective ...

Today’s installment of campaign-related news items from across the country. * In Georgia’s upcoming gubernatorial race, Democrats hoped to see a high-profile contender run, and now they have ...

Subscribe Login Register Log out My Profile Subscriber Services Search PGe NEWSLETTERS PG STORE ARCHIVES OBITUARIES JOBS PUBLIC NOTICES CLASSIFIEDS EVENTS PETS CONTACT US ADVERTISING CAREER ...

UnitedHealth Group has agreed to pay at least $20.25 million to settle a U.S. Department of Labor lawsuit that alleged a division of the company, called UMR, wrongly denied thousands of claims to ...

INDIANAPOLIS — If you're looking to ring in the new year with live entertainment in downtown Indianapolis, this deal could help you out! Live Nation is offering $20.25 tickets to more than 50 live ...

State government employees covered under the American Federation of State, County and Municipal Employees Council 13 contract could see pay raises totaling 20.25% over the next four years. A ...

The above-mentioned drug is therapeutically equivalent to the reference listed drug product (RLD) - AndroGel 1.62 per cent of AbbVie Inc. The drug is indicated for replacement therapy in adult males ...

The AndroGel ® (testosterone gel) brand and generic had U.S. sales of approximately $815.6 million MAT for the most recent twelve months ending in February 2019 according to IQVIA Health*.

Lupin's testosterone gel, 1.62 percent (20.25 mg/1.25 g pump actuation), is the generic equivalent of AbbVie Inc's AndroGel, 1.62 percent, Lupin said in a BSE filing. Quoting IQVIA MAT December ...

Lupin’s Testosterone Gel, 1.62% (20.25 mg/1.25 g pump actuation), is the generic equivalent of AbbVie’s AndroGel, 1.62%. It is indicated for replacement therapy in males for conditions ...

Testosterone gel 1.62% (20.25 mg/1.25 g pump actuation) is the generic equivalent of AbbVie’s AndroGel, 1.62%, first approved by the FDA in 2011. It is indicated for replacement therapy in men ...

The FDA approves Perrigo's generic version of AbbVie's (NYSE:ABBV +0.4%) Androgel Topical Gel, 1.62% packets (20.25 mg/1.25 g packet and 40.5 mg/2.5 g packet) for testosterone replacement therapy.